- Condition: Colorectal Cancer
Interventions: Procedure: Surgical resection of recurrent colorectal cancer; Drug: Chemokine-modulatory (CKM) regimen
Sponsors: University of Pittsburgh; University of Pittsburgh
Not yet recruiting - verified March 2012 - Condition: Other Acute Postoperative Pain
Interventions: Drug: Indomethacin; Drug: Indomethacin; Drug: Indomethacin; Drug: Celecoxib; Drug: Placebo
Sponsors: Iroko Pharmaceuticals, LLC; Iroko Pharmaceuticals, LLC
Recruiting - verified February 2012 - Conditions: Uterine Fibroids; Uterine Artery Embolization
Interventions: Drug: pregabalin/celecoxib; Drug: pregabalin/placebo; Drug: celecoxib/placebo; Drug: Placebo group
Sponsors: Northwestern University; Northwestern University
Recruiting - verified March 2012 - Condition: Bipolar Depression
Interventions: Drug: ESC + CBX; Drug: ESC + PBO.; Drug: ESC+CBX
Sponsors: Loyola University; Loyola University; Stanley Medical Research Institute
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: Celecoxib; Drug: Placebo; Drug: Cholecalciferol
Sponsors: University of North Dakota; University of North Dakota; Department of Defense
Recruiting - verified August 2011 - Conditions: Sarcoma; Melanoma; Epithelial Malignancies; Pleural Malignancy
Interventions: Biological: Epigenetically Modified Autologous Tumor; Drug: Cyclophosphamide; Drug: Celecoxib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Sarcoma; Melanoma; Epithelial Malignancies; Pleural Malignancies
Intervention: Biological: Allogenic Tumor Cell Vaccine (K562)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Mesolthelioma; Esophageal Cancer; Lung Cancer
Interventions: Drug: Celecoxib; Drug: ISCOMATRIX (TM) Adjuvant; Biological: Autologous Tumor Cell Vaccine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Lung Cancer; Esophageal Cancer; Malignant Pleural Mesothelioma; Thymoma; Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562); Drug: Celecoxib; Drug: cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Mouth Neoplasms
Interventions: Drug: 1,25-dihydroxyvitamin D3; Drug: celecoxib; Drug: 1,25-dihydroxyvitamin D3 + celecoxib
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012 - Condition: Arthritis, Juvenile Rheumatoid
Interventions: Drug: Celecoxib; Drug: Naproxen
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Recurrent Respiratory Papillomatosis
Interventions: Drug: celebrex (celecoxib); Drug: placebo capsules
Sponsors: North Shore Long Island Jewish Health System; North Shore Long Island Jewish Health System; National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified January 2012 - Condition: Lung Cancer
Interventions: Drug: celecoxib; Drug: Docetaxel; Drug: pemetrexed disodium; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2012 - Condition: Precancerous Conditions
Intervention: Drug: Erlotinib & Celecoxib
Sponsors: Emory University; Emory University; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Condition: Rectal Cancer
Intervention: Drug: Oxaliplatin, Capecitabine, Celecoxib with Radiation
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011 - Conditions: Autonomic Failure; Orthostatic Hypotension
Interventions: Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: abdominal binder; Device: abdominal binder (sham)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Pancreas Neoplasms
Intervention: Drug: celecoxib
Sponsors: Indiana University; Indiana University School of Medicine
Recruiting - verified March 2012 - Condition: Lung Cancer
Intervention: Drug: celecoxib
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
 |
Celebrex Clinical Trials |
